Cargando…
A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma
Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the correspon...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867041/ https://www.ncbi.nlm.nih.gov/pubmed/36676104 http://dx.doi.org/10.3390/life13010155 |
_version_ | 1784876243675512832 |
---|---|
author | Malaina, Iker Martínez, Luis Montoya, Juan Manuel Alonso, Santos Boyano, María Dolores Asumendi, Aintzane Izu, Rosa Sanchez-Diez, Ana Cancho-Galan, Goikoane M. de la Fuente, Ildefonso |
author_facet | Malaina, Iker Martínez, Luis Montoya, Juan Manuel Alonso, Santos Boyano, María Dolores Asumendi, Aintzane Izu, Rosa Sanchez-Diez, Ana Cancho-Galan, Goikoane M. de la Fuente, Ildefonso |
author_sort | Malaina, Iker |
collection | PubMed |
description | Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the corresponding patient. Methods: We extracted the 1134 most frequent mutations in melanoma, and we associated each of them to a vector with 10 components estimated with different bioinformatics tools, for which we found an aggregated value according to a set of weights, and then we ordered them in decreasing order of the scores. Results: We prepared a universal table of the most frequent mutations in melanoma ordered in decreasing order of viability to be used as candidate vaccines, so that the selection of a set of appropriate peptides for each particular patient can be easily and quickly implemented according to their specific mutanome and transcription profile. Conclusions: We have shown that the techniques that are commonly used for the design of personalized anti-tumor vaccines against malignant melanoma can be adapted for the design of universal rankings of neoantigens that originate personalized vaccines when the mutanome and transcription profile of specific patients is considered, with the consequent savings in time and money, shortening the design and production time. |
format | Online Article Text |
id | pubmed-9867041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98670412023-01-22 A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma Malaina, Iker Martínez, Luis Montoya, Juan Manuel Alonso, Santos Boyano, María Dolores Asumendi, Aintzane Izu, Rosa Sanchez-Diez, Ana Cancho-Galan, Goikoane M. de la Fuente, Ildefonso Life (Basel) Article Background: The main purpose of this article is to introduce a universal mathematics-aided vaccine design method against malignant melanoma based on neoantigens. The universal method can be adapted to the mutanome of each patient so that a specific candidate vaccine can be tailored for the corresponding patient. Methods: We extracted the 1134 most frequent mutations in melanoma, and we associated each of them to a vector with 10 components estimated with different bioinformatics tools, for which we found an aggregated value according to a set of weights, and then we ordered them in decreasing order of the scores. Results: We prepared a universal table of the most frequent mutations in melanoma ordered in decreasing order of viability to be used as candidate vaccines, so that the selection of a set of appropriate peptides for each particular patient can be easily and quickly implemented according to their specific mutanome and transcription profile. Conclusions: We have shown that the techniques that are commonly used for the design of personalized anti-tumor vaccines against malignant melanoma can be adapted for the design of universal rankings of neoantigens that originate personalized vaccines when the mutanome and transcription profile of specific patients is considered, with the consequent savings in time and money, shortening the design and production time. MDPI 2023-01-05 /pmc/articles/PMC9867041/ /pubmed/36676104 http://dx.doi.org/10.3390/life13010155 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Malaina, Iker Martínez, Luis Montoya, Juan Manuel Alonso, Santos Boyano, María Dolores Asumendi, Aintzane Izu, Rosa Sanchez-Diez, Ana Cancho-Galan, Goikoane M. de la Fuente, Ildefonso A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma |
title | A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma |
title_full | A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma |
title_fullStr | A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma |
title_full_unstemmed | A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma |
title_short | A Universal Antigen-Ranking Method to Design Personalized Vaccines Targeting Neoantigens against Melanoma |
title_sort | universal antigen-ranking method to design personalized vaccines targeting neoantigens against melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867041/ https://www.ncbi.nlm.nih.gov/pubmed/36676104 http://dx.doi.org/10.3390/life13010155 |
work_keys_str_mv | AT malainaiker auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT martinezluis auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT montoyajuanmanuel auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT alonsosantos auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT boyanomariadolores auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT asumendiaintzane auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT izurosa auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT sanchezdiezana auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT canchogalangoikoane auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT mdelafuenteildefonso auniversalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT malainaiker universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT martinezluis universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT montoyajuanmanuel universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT alonsosantos universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT boyanomariadolores universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT asumendiaintzane universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT izurosa universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT sanchezdiezana universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT canchogalangoikoane universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma AT mdelafuenteildefonso universalantigenrankingmethodtodesignpersonalizedvaccinestargetingneoantigensagainstmelanoma |